Table 4

Total ambulatory care expenditures according to time and treatment phase for patients (€)
2005 2006 2007 2008 2009 2010
N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD
Patients with Normal Renal Function
Monotherapy 5,507 2,703 3,333 5,543 2,711 3,407 5,682 2,821 3,542 5,921 2,971 3,916 5,538 2,980 3,876 4,353 3,017 3,829
Double therapy 2,324 2,884 3,113 2,587 2,935 3,206 2,762 3,095 3,622 2,839 3,125 3,611 2,786 3,171 3,861 2,503 3,308 4,045
Triple therapy 328 3,473 3,121 406 3,295 3,013 505 3,313 2,938 587 3,180 3,011 658 3,264 3,312 728 3,609 3,801
Insulin therapy 898 6,759 5,203 1,029 6,800 5,192 1,150 7,063 5,573 1,214 7,058 5,903 1,256 7,228 5,658 1,032 7,398 5,487
Non diabetic patients 27,389 1,715 2,914 28,962 1,767 3,060 30,618 1,866 3,261 32,103 1,994 3,475 31,128 2,150 3,979 26,253 2,166 4,102
Patients with Declining Renal Function
Monotherapy 282 4,148 4,258 339 4,267 4,426 393 4,396 4,811 465 4,897 6,427 518 4,149 4,637 411 4,226 5,369
Double therapy 157 3,773 3,144 228 3,603 3,628 266 3,667 3,257 308 3,892 4,004 310 3,891 4,623 267 4,159 5,268
Triple therapy 27 4,244 3,641 41 3,105 1,617 45 4,052 3,396 69 4,203 4,411 71 3,387 3,027 78 4,032 4,329
Insulin therapy 136 10,772 9,335 188 10,227 8,882 240 10,644 10,731 294 10,499 10,185 359 11,155 11,188 267 11,344 11,185

Guelfucci et al.

Guelfucci et al. BMC Endocrine Disorders 2013 13:15   doi:10.1186/1472-6823-13-15

Open Data